Abingworth, a UK-based life sciences investor backed by Carlyle, is raising up to $1.5bn for clinical trials and royalty partnerships with pharmaceutical companies. Recent collaborations with Gilead Sciences and Teva demonstrate the fund’s focus on funding late-stage trials for promising drugs. Abingworth’s successful track record in phase-three trials, coupled with the current demand for new medicines, positions the fund as an attractive option for pharma companies seeking to maximize drug development opportunities.
Full Article
Trump’s invitation to Xi for inauguration could signal a ‘grace period’ before China faces tariffs
President-elect Donald Trump has invited Chinese President Xi Jinping to his inauguration next month, potentially indicating a delay in imposing tariffs on Beijing as Trump begins his second term. This move, as suggested by advisory firm Signum Global, could signal a more diplomatic approach towards China under the new administration. The invitation reflects a possible shift in U.S.-China relations, hinting at a desire for dialogue and negotiation rather than immediate punitive measures. Full Article
Read more